Renalytix Plc (NASDAQ:RNLX) Short Interest Up 23.8% in June

Renalytix Plc (NASDAQ:RNLX) was the recipient of a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 292,900 shares, an increase of 23.8% from the June 15th total of 236,600 shares. Based on an average daily trading volume, of 294,100 shares, the days-to-cover ratio is presently 1.0 days.

Institutional Trading of Renalytix

A hedge fund recently raised its stake in Renalytix stock. Pinnacle Associates Ltd. increased its stake in shares of Renalytix Plc (NASDAQ:RNLX) by 7.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 846,534 shares of the company’s stock after buying an additional 60,572 shares during the period. Pinnacle Associates Ltd. owned 1.69% of Renalytix worth $330,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 9.92% of the company’s stock.

Renalytix Price Performance

NASDAQ:RNLX traded down $0.02 during trading hours on Monday, reaching $0.33. The company’s stock had a trading volume of 2,037,445 shares, compared to its average volume of 1,750,097. Renalytix has a one year low of $0.22 and a one year high of $3.66. The business’s 50-day moving average is $0.44 and its 200-day moving average is $0.61. The company has a market cap of $25.30 million, a price-to-earnings ratio of -0.83 and a beta of 2.78.

Renalytix (NASDAQ:RNLX) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.08) EPS for the quarter. Renalytix had a negative net margin of 1,687.80% and a negative return on equity of 1,008.88%. The company had revenue of $0.54 million for the quarter. On average, sell-side analysts predict that Renalytix will post -0.3 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Renalytix in a research note on Friday.

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.